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Abstract
Objective—Measures for assessing patient-reported outcomes (PROs) that may have initially 
been developed for research are increasingly being recommended for use in clinical practice as 
well. While psychometric rigor is essential, this paper focuses on pragmatic characteristics of 
PROs that may enhance uptake into clinical practice.
Methods—Three sources were drawn upon in identifying pragmatic criteria for PROs: 1) 
selected literature review including recommendations by other expert groups; 2) key features of 
several model public domain PROs; 3) the author' experience in developing practical PROs.
Results—Eight characteristics of a practical PRO include: 1) actionability (i.e., scores guide 
diagnostic or therapeutic actions/decision-making); 2) appropriateness for the relevant clinical 
setting; 3) universality (i.e., for screening, severity assessment, and monitoring across multiple 
conditions); 4) self-administration; 5) item features (number of items and bundling issues); 6) 
response options (option number and dimensions, uniform vs. varying options, timeframe, 
intervals between options); 7) scoring (simplicity, interpretability); and 8) accessibility 
(nonproprietary, downloadable, available in different languages and for vulnerable groups, 
incorporated into electronic health records)
Conclusion—Balancing psychometric and pragmatic factors in the development of PROs is 
important for accelerating the incorporation of PROs into clinical practice.
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Measurement is a vital aspect of patient care, necessary for diagnosis, grading of disease 
severity, estimating prognosis, and monitoring and adjusting treatment. However, not all 
relevant outcomes can be assessed with a device, a laboratory test, a physical finding, or 
some other data gathered independent of the patient's perceptions and voice. Symptoms, 
health-related quality of life, and certain other domains rely exclusively or predominantly on 
patient-articulated feelings and experiences and therefore depend upon reliable and valid 
patient-reported outcome (PRO) measures. Indeed, the NIH has recognized the importance 
of PROs by investing heavily in the development of the Patient-Reported Outcome 
Measurement Information Systems (PROMIS) scales(1) freely available at www.promis.org.
In this paper, we propose several factors to consider when developing a practical PRO 
measure. By practical we mean those features that will enhance a measure's adoption and 
use in clinical practice. William James, a key founder of the pragmatic school of American 
philosophy, defined truth as that “which works” or has “cash value”.(2) The “cash value” of 
a PRO is its relevance to patient care.
The practical characteristics outlined in Table 1 do not include the classical psychometric 
requirements of a scale, such as reliability or validity, nor do they speak to the many basic 
and advanced procedures for scale development (e.g., item selection, cognitive testing, 
differential item functioning, item response theory). Psychometric standards are a given and 
well-described in consensus reports on PROs.(3,4) Indeed, most PROs gravitate from 
research into practice and practical considerations should not override the necessity for 
psychometric rigor in scale development. Table 2 compares our pragmatic recommendations 
with those of several other groups(5-7), although the latter groups may sometimes use 
alternative terms or raise different issues related to the 8 characteristics as well as suggest 
other practical considerations.
Scale development is often a low priority for sponsors that support biomedical research, 
thereby constraining the funding available for evaluating every psychometric nuance of a 
PRO. This is especially true when a measure is developed and “second-generation” 
questions arise, such as: 1) differences between modes of administration (e.g., self-report vs. 
interview; patient vs. proxy; in-person vs. telephone); 2) standards for translating into 
different languages; 3) abbreviating or modifying versions of the original measure. 
Therefore, we advocate a balance between psychometric and pragmatic values in all stages 
of PRO development and validation. The OMERACT guidelines exemplify a similar 
balance even for outcome measures used in clinical trials by not only recommending truth 
and discrimination as psychometric criteria but also feasibility (e.g., can the measure be 
applied easily, given constraints of time, money, and interpretability?) as a pragmatic 
criterion.(8)
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1. Actionability
The utility of a PRO in clinical practice is enhanced when providers know how to translate 
scores into concrete actions, such as further diagnostic evaluation or testing, treatment 
initiation or adjustment, or subspecialty referrals.(5,9) Simply providing more data to busy 
practitioners who already have enormous competing demands for their time in a clinical 
encounter often limited to 15 minutes or less can be more frustrating than empowering. 
(10,11) On the other hand, data that efficiently informs specific actions will be embraced. 
For example, a high depression score prompting an increase in the antidepressant dose can 
be as useful as an elevated serum cholesterol that leads to modifying lipid-lowering therapy. 
A useful preference-based question asks patients if they desire treatment for their symptoms.
(12,13) This provides a patient-centered criterion for interpreting PRO scores in the 
individual person, since different patients may desire (or alternatively refrain from) 
treatment at different symptom thresholds.
What factors might make a PRO not actionable in a particular clinical setting?
a) The target of the PRO may be outside the purview of a particular clinician who in turn 
lacks referral options. For example, social functioning is a domain many physicians neither 
have the skills nor resources to address. Thus, unless a social work referral or community 
resource are readily available, knowledge of impaired social functioning in the absence of 
explicit actions to efficiently address these impairments can be demoralizing for the 
clinician and offer false hope to the patient.
b) The target may be within the purview of the clinician but resource-contingent, such that 
in the absence of these resources, use of the PRO will not benefit patient outcomes. For 
example, multiple trials have shown that depression screening alone does not enhance 
outcomes(14) but depression screening combined with other systems enhancements does.
(15) This has led the US Preventive Services Task Force to recommend use of a depression 
screening measure only if systems are in place to adequately optimize depression outcomes.
(16)
c) The domain assessed by the PRO may be excessively bundled, in which case a particular 
score cannot inform a targeted action without efforts by the clinician to conduct a 
differential diagnosis of what may be leading to an elevated score and then determine what 
is and is not actionable. For example, a physical function or role function score may be 
abnormal due to numerous medical and nonmedical factors. However, there is no discrete 
“physical function” or “role function” pill, procedure, or other specific therapy. Still, such 
summary scores might be useful at a higher level (e.g., assessing quality of care or systems-
based interventions provided to patient panels or populations).
2. Setting-appropriate
The clinical setting and the actionable goals of that setting may dictate the length, 
specificity, and granularity of a particular PRO.(7) For example, brief PROs capturing 
multiple domains may be more suitable for primary care, whereas longer PROs focused on 
one or several disease-specific domains may be preferable for specialty clinics. PROs can 
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also be used in non-office-based settings, such as hospitals or long-term care facilities. The 
rationale for shorter PROs in the general medical setting is not only because the clinician has 
to attend to more conditions but also because longer measures targeting multiple domains 
increase the respondent burden for the patient. For example, a 30-item PRO with 5 items for 
each of 6 domains that is used in primary care would have a comparable respondent burden 
as a 30-item cardiovascular disease-specific PRO completed by patients in a cardiology 
clinic. One caveat – longer disease-specific measures are only justified for a specialty setting 
if they lead to different or differential or distinctive diagnostic or treatment actions. For 
example, if a brief depression or pain measure performs as well as a longer one, it may 
suffice in all settings.
3. Universal
Measures can be used to screen for a condition, to establish a diagnosis, to assess severity, to 
monitor treatment response and to provide prognostic information about the future course of 
a disease.(5,17) After all, the same blood pressure cuff is used to screen for, diagnose, and 
assess the severity of hypertension as well as monitor the adequacy of blood pressure 
treatment. One example of a multi-purpose PRO is the PHQ-9 which can be used as to 
assess depression severity, establish probable diagnoses, and monitor treatment. (18) It is 
also valid across a range of ages (adolescent to geriatric populations)(19,20)as well as racial/
ethnic, educational, and sociocultural factors.(18,21). Likewise, a “cross-cutting” measure 
that can be used in multiple conditions and diseases has certain advantages. Some symptoms 
(pain, fatigue, depression, sleep disturbances) occur in many medical and mental disorders, 
and patients frequently have a number of comorbid conditions. Similarly, functional status 
and health-related quality of life domains often transcend specific diseases. The degree to 
which a PRO is broadly applicable across multiple conditions increases its utility and 
obviates the need for multiple measures of the same domain to cover different diseases. 
Indeed, this has been a key principle in developing PROMIS measures.(22)
4. Self-administered
As opposed to measures of bodily fluids (e.g., laboratory tests of blood, urine, sputum) or 
organs (physical examination, radiographic imaging, pathological specimens), assessment of 
symptoms relies largely or exclusively on patient report. In this regard, self-administered 
measures can minimize the amount of time devoted to mere data collection allowing the 
clinician more time to discuss the meaning and treatment implications of elevated PRO 
scores. Second, self-administered measures may lead to greater detection of problems in 
sensitive areas like substance use or sexual function.(23) Third, self-administered measures 
are not influenced by clinician or interviewer biases that can occur when an external 
observer superimposes his or her interpretation of symptoms that only the patient can 
accurately grade. That being said, it is also desirable if a measure is reliable and valid across 
various modes of administration (e.g., self- vs. interviewer administered; in-person vs. 
telephone vs. web-based) or, in some cases, even different perspectives (e.g., a clinical 
observer or a proxy when assessing pain or depression in children or in adults with cognitive 
impairment).(20,24,25)
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5. Items
Brevity is generally desirable; we arbitrarily define a brief measure as “single digits” (less 
than 10 items) and an ultra-brief measure as 1 to 4 items. Another metric might be the length 
of time it takes an individual to complete a PRO or a set of PROs – anything requiring more 
than 1 to 5 minutes may be perceived as excessive in busy outpatient settings . As noted, the 
minimal length of a measure may be dictated by the purpose (e.g., screening vs. monitoring), 
although there is some evidence that even ultra-brief PROs may be perform comparably to 
longer measures for case detection(26,27) and, for some conditions, sufficiently sensitive to 
change for outcome monitoring.(28-30) The option to administer PROMIS scales using a 
computerized adaptive testing (CAT) approach allows a precise assessment of a domain 
with as few as 7 to 8 items and also provides automatic calculation of scores along with 
normative information pertaining to the US general population.
Although items that focus on a single symptom or problem are generally desirable, bundling 
more than one symptom or problem into a compound item is occasionally justifiable. One 
type of compound item uses a few synonyms for the same symptom (e.g., “feeling down, 
sad, blue, or depressed”; “feeling tired or having little energy”; “feeling your heart pound or 
race”), since some respondents may identify more with one synonym than another. Some 
compound items ask about different symptoms but ones that are conceptually or 
mechanistically related (i.e., emanating from the same organ system or disease), such as 
“nausea or vomiting”; “constipation or diarrhea”; “pain in your arms, legs or joints”. Here 
the testing and/or treatment may be the same, so asking separate items is unnecessary from a 
pragmatic standpoint. A third type of compound item asks about symptoms not so closely 
related (at times, even opposites) but any one of which fulfills the same diagnostic criterion. 
For example, the PHQ-9 depression scale has one item about “poor appetite or overeating”, 
another about “trouble falling or staying asleep or sleeping too much”, and still another 
about “feeling bad about yourself — or that you are a failure or have let yourself or your 
family down”.
6. Response options
Dimensions of a symptom or problem commonly assessed by response options include: a) 
Frequency (how often): e.g., never/rarely/sometimes/often/always; b) Severity/intensity 
(how much), e.g., not at all/a little bit/somewhat/quite a bit/very much; and c) Impairment, 
captured by modifiers such as “How much did (symptom) interfere with ...?” or “How much 
were you bothered (distressed) by (symptom)?” or “How difficult did (symptom) make it to 
do your...?”(31) A few measures capture multiple dimensions (e.g., the Memorial Symptom 
Assessment Scale asks about frequency, severity, and impairment for each symptom 
endorsed by the patient).(32) Most PROs, however, settle on one dimension per item to 
reduce respondent burden and to simplify scoring. Moreover, it is possible that many 
respondents recognize the ordinal nature of a response set, regardless of dimensions or 
words used, understanding that as they go from left to right a symptom is either being 
ranked as better or worse, and they situate themselves on this ordinal scale accordingly.
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The number of response options when the choices are words typically range from 3 to 5; it is 
not clear that many respondents can make finer distinctions than this.(33-35) Likert-type 
scales sometimes include up to 7 options, although often with only 2 or 3 verbal anchors (for 
the extremes of the scale and sometimes the middle point). Numerical rating scales may 
range up to 11 points (e.g., the commonly-used 0 to 10 pain scale). Even if the decision is 
made to assess only one dimension per symptom, the decision remains of whether to have 
more than one response set for different symptoms or for different subscales within the 
measure. For example, the PHQ assesses 5 different types of mental disorders, and does not 
use the same response set for each disorder. Similarly, the PROMIS profiles use different 
response sets for different scales, and sometimes more than one response set for subsets of 
items within the same scale. The advantage of a uniform response set is that respondents do 
not need to make the cognitive shifts that might be necessary when moving from one 
response set to another. The disadvantage is that a particular response set may appear more 
suitable for certain items or subscales, and forcing all items into the same Procrustean bed of 
responses may be a poor fit.
Selecting the timeframe for an item (e.g., past week, past 2 weeks, past month) is a 
balancing act between recall accuracy (presumably favored by shorter timeframes) and the 
benefits of “time-averaging” (so that one bad day or week does not overestimate the 
magnitude of the problem). Even with longer recall periods, patient grading of a symptom 
may be overly influenced by its current or recent magnitude.(36) Another factor that may 
affect the selection of timeframe is the length of time one expects a symptom to improve, 
either naturalistically or in response to treatment. For example, pain may respond more 
rapidly to treatment than depression, and physical and role functioning improvement may 
lag behind symptom improvement.
Deciding on the appropriate intervals between options within a response set is also 
important. Some options may seem quite close (e.g., “never” and “rarely”) but can be 
appropriate depending upon symptom prevalence, floor and ceiling effects, and other 
factors. When the distance between items appears small (e.g., one scale has options of “a 
great deal” and “a very great deal” (37)), it is important to determine if respondents can 
actually discriminate such subtle differences. Conversely, one should also ask if there are 
“gaps” between items (e.g., in our experience with the PHQ-9 some respondents desired an 
option between “not at all” and “several days”).
7. Scoring
Simplicity in scoring facilitates clinical uptake. Easy scoring is exemplified by a measure 
that provides a single summative score of individual items without the complexity of 
reverse-scored items, transformation of raw scores into standardized scores, or several 
subscale scores for a single construct.(17) Reverse scoring complicates the simple addition 
of item scores into a total score and requires respondents to shift the direction of their 
thinking about responses in moving from one item to another. The rationale that reverse 
scored items aid in detecting inconsistent responses or response sets (the tendency to check 
the same response option for most or all of the symptoms) has poor empiric support; indeed, 
such items may decrease reliability and validity(38-41) and increase the burden for certain 
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respondents(42,43). Similarly, the need to transform raw scores into a standardized score 
through a formula or other conversion process also complicates clinical use. Finally, 
clinicians like easy-to-remember cutpoints whenever possible; for example, 5, 10, and 15 
represent thresholds for mild, moderate, and severe levels of symptoms on the PHQ 
depression, anxiety, and somatization scales.(18)
What is the role of composite scores? As noted earlier, a specific symptom may be assessed 
along several dimensions in which case the clinician may be provided each score separately, 
a composite score, or both. For example, some experts believe it is important to measure 
pain severity and pain interference separately(44), although recent evidence has shown that a 
single composite pain score is equally responsive.(29,30) Certainly, a single rather than 
multiple scores for the same symptom is easier to act upon: how does the clinician treat and 
follow two different numbers for the same symptom, and what action is taken if the numbers 
are discordant? A second type of composite score combines separate scores for symptom 
domains that, while conceptually and empirically distinct, commonly overlap, strongly 
correlate with one another, and may share common treatments. This is the case with two 
mood symptoms – depression and anxiety – for which it may be valuable to have both 
separate and composite scores.(45-47) A third type of composite score is for symptoms that, 
although clearly distinct from one another, commonly cluster, have adverse effects on one 
another, and may benefit from co-management. For example, the SPADE pentad – sleep, 
pain, anxiety, depression, and energy (fatigue) – comprises the most prevalent, disabling and 
undertreated symptom cluster in cancer patients as well in patients with many other medical 
and mental disorders.(48,49) While there are symptom-specific treatments for each, there 
are also treatments that work across more than one SPADE symptom(49,50), in which case 
there may be benefits for clinicians having both individual symptom scores as well as a 
composite score. Finally, a composite score of multiple seemingly diverse symptoms may 
represent an underlying construct for which there are specific treatments. For example, 
patients who report multiple somatic symptoms can be recognized as having somatization or 
a somatoform disorder which in turn have evidence-based treatments.(51) In such cases, a 
somatic symptom composite score may even be more useful than multiple individual item-
level symptom scores.(18,52,53)
Interpretability of scores is important (6,7), including establishing cutpoints that signify a 
threshold for case identification or clinical action, determining how much change in a score 
represents meaningful improvement or worsening, clarifying directionality (i.e., are higher 
or lower scores worse?), and aiming for scores that can be easily understood by both 
clinicians and patients in order to facilitate communication and mutual decision-making.
8. Accessibility
Several factors enhance accessibility of a PRO to clinicians and patient populations. First, a 
measure that is nonproprietary (i.e., available at no cost) is more readily used than one for 
which there is a charge each time the scale is administered.(54). Second, a measure that is 
accessible and downloadable from the Internet enhances clinical use. Examples of public 
domain PROs that are easily available through the Internet include the PROMIS and PHQ 
scales among others. Third, the more languages into which a PRO has been translated, the 
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greater is its global reach and applicability to diverse populations. Fourth, the ability to 
administer the PRO to vulnerable populations is desirable.
Electronic administration of the measure using automated approaches, either through 
computerized administration in the clinic or by interactive voice recorded (IVR) or web-
based data collection outside the clinic, facilitates both accessibility and efficiency of use.
(55). The PROMIS Assessment Center (www.promis.org) provides a free web-based tool 
for data collection. Graphic reports of PROs over time can help direct the clinician to salient 
issues including changes over time as well as scores that exceed clinical cut offs.(7) Another 
important step is to incorporate PRO results into the electronic medical records which allows 
clinicians to not only have the scores “just in time” for decision-making but to also track the 
trajectory of symptoms over time as treatment is monitored.(56,57)
Strong psychometrics and practical characteristics are two features essential to the use of 
PROs in clinical settings. Other factors that may influence uptake include using PROs as a 
metric for assessing quality of care, incentivizing use by payers, incorporating PROs into 
guidelines for management of particular diseases, and demonstrating to clinicians and 
patients the utility of measurement-based care for optimizing treatment outcomes. The use 
of PROs to evaluate and monitor outcomes that principally rely on patient input is gathering 
momentum(5,58,59) and to accelerate this movement, practical considerations are essential. 
In the words of the 20th century pragmatic philosopher, Richard Rorty: “It is the vocabulary 
of practice rather than of theory, of action rather than contemplation, in which one can say 
something useful about truth.”(60) The same might be said about patient-reported outcome 
measures.
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What is new?
Key points
• Clinical uptake of patient-reported outcome (PRO) measures requires pragmatic 
as well as psychometric considerations.
• Eight pragmatic characteristics include actionability, setting-appropriateness, 
universality, self-administration, item features, response options, scoring, and 
accessibility.
• Examples from the literature as well as public domain PROs such as the Patient 
Health Questionnaire (PHQ) and Patient-Reported Outcome Information System 
(PROMIS) scales as well as other PROs exemplify these pragmatic 
considerations
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Table 1
Characteristics of a Practical Patient-Reported Outcome Measure
Characteristic Comment
1. Actionable Do scores guide diagnostic or therapeutic action/decision-making?
2. Setting-appropriate Is the target audience: a) primary care outpatients; b) specialty clinic
outpatients; c) hospitalized patients; d) extended care/other settings?
3.
a
b
Universal
• Multi-purpose
• Cross-cutting
Can measure screen, diagnose, assess severity, and monitor therapy?
Can measure be used in multiple different diseases and conditions?
4. Self-administered Is completion of the measure by the patient alone reliable and valid?
5.
a
b
Items
• Number
• Bundling
Is the measure sufficiently brief?
Are items simple (1 symptom) or compound (≥ 2 related symptoms)?
6.
a
b
c
d
e
Response options
• Dimension
• Number
• Uniformity
• Time frame
• Intervals
What is being assessed – frequency, severity, impairment, other?
How many response options per item (3, 4, 5, or more)?
Is there one response set for all items (vs. varying response sets)?
What is the optimal recall period (days, weeks, months, or other)?
Is there appropriate spacing between options? Are there gaps?
7.
a
b
c
Scoring
• Simplicity
• Number of scores
• Interpretability
Can reverse scored items or score transformation be avoided?
Are there subscale scores, a composite score, or both?
What are meaningful clinical outpoints and changes over time?
8.
a
b
c
d
e
Accessibility
• Nonproprietary
• Downloadable
• Translations
• Vulnerable groups
• Electronic
Is the measure public domain (i.e., available at no cost)?
Is the measure easy to access through the Internet?
Has the measure been translated into multiple languages?
Can the measure be completed by those with low literacy, disabilities,
or impaired capacity (including proxy completion when necessary)?
Is the measure captured through automation and in electronic records?
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